Glucocorticoid-induced bone loss in dermatologic patients: An update

Archives of Dermatology

Volumn 142, Issue 1, 2006, Pages 82-90

  Summey, Brett T ^a   Yosipovitch, Gil ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CATHEPSIN K INHIBITOR; CLODRONIC ACID; COLECALCIFEROL; CORTICOSTEROID; ESTROGEN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PREDNISONE; PROGESTERONE; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TESTOSTERONE; ZOLEDRONIC ACID;

APOPTOSIS; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CALCIUM ABSORPTION; CALCIUM EXCRETION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPERCALCIURIA; MENOPAUSAL SYNDROME; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; TESTOSTERONE BLOOD LEVEL;

GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RISK FACTORS; SKIN DISEASES;

EID: 30844435903     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.1.82     Document Type: Review

References (79)

1. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis, II: relation between steroid dose and steroid associated side effects. Ann Rheum Dis. 1989;48:662-666.
2. Reid IR. Preventing glucocorticoid-induced bone loss. N Engl J Med. 1997;337:420-421.
3. Baltzan MA, Suissa S, Bauer DC, Cummings SR. Hip fractures attributable to corticosteroid use. Lancet. 1999;353:1327.
4. Center JR, Nguyen TV, Schneider D, Sambrook PM, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878-882.
5. Goh JC, Bose K, Das D. Pattern of fall and bone mineral density measurement in hip fractures. Ann Acad Med Singapore. 1996;25:820-823.
6. National Osteoporosis Foundation. Osteoporosis: a debilitating disease that can be prevented and treated. Availabe at: http://www.nof.org/osteoporosis. Last updated 2004.
7. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis. Osteoporos Int. 2002;13:777-787.
8. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996;313:344-346.
9. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 1983;309:265-268.
10. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995;54:49-52.
11. Michel BA, Bloch DA, Fries JF. Predictors of fracture in early RA. J Rheumatol. 1991;18:804-808.
12. Dykman TR, Flock OS, Murphy WA, et al. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic disease. Arthritis Rheum. 1985;28:361-368.
13. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in pre-menopausal asthma patients receiving long-term inhaled steroids. Chest. 1994;105:1722-1727.
14. Liu RH, Albrecht J, Werth V. Cross-sectional study of bisphosphonate use in dermatology patients on long-term oral steroids. J Invest Dermatol. 2005;298:A40.
15. Buckley L, Marquez M, Hudson JO, et al. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol. 1998;25:2195-2202.
16. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int. 1997;7:390-406.
17. Adachi JD, Ollszynski WP, Hanley D, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228-251.
18. Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Arch Dermatol. 2001;137:477-481.
19. Young CA, Williams IR, MacFarlane IA. Unrecognized Cushing's syndrome and adrenal suppression due to topical clobetasol propionate. Br J Clin Pract. 1991;45:61-62.
20. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest. 1998;102:274-282.
21. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85:2907-2912.
22. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73-81.
23. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegrin in osteoporosis and vascular disease. Calcif Tissue Int. 2004;74:103-106.
24. Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisolism. J Clin Invest. 1977;60:253-260.
25. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism. 1983;32:151-156.
26. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. In: Technical Report: Series 843. Geneva, Switzerland: World Health Organization; 1994.
27. Licata A. Osteoporosis in men: suspect secondary disease first. Cleve Clin J Med. 2003;70:247-254.
28. Van Staa T, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
29. Selby PL, Halsey JP, Adams KR, et al. Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res. 2000;15:952-956.
30. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
31. Luengo M, Picado C, Del Rio L, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax. 1991;46:803-806.
32. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-899.
33. Bone and Tooth Society. Glucocorticoid-Induced Osteoporosis: Guidelines for Prevention and Treatment. London, England: National Osteoporosis Society, Royal College of Physicians; 2002.
34. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid induced osteoporosis. J Bone Miner Res. 2002;17:1512-1526.
35. Amin S, LaValley MP, Simms RW, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. 1999;42:1740-1751.
36. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002;9:84-101.
37. Homik J, Suarez ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis [Cochrane Review]. Oxford, England: Cochrane Library; 2000: Issue 2.
38. Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am. 1998;27:465-483.
39. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alfacalcidol and calcitriol in primary and corticosteroid induced osteoporosis. Osteoporos Int. 2004;15:301-310.
40. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res. 2003;18:919-924.
41. Plotkin LI, Weinstein TS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363-1374.
42. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339:292-299.
43. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo controlled extension trial. Arthritis Rheum. 2001;44:202-211.
44. Eastell R, Devogelaer J-P, Peel NFA, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000;11:331-337.
45. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum. 1999;42:2309-2318.
46. Reid DM, Hughes RA, Laan RM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trial. J Bone Miner Res. 2000;15:1006-1013.
47. Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol. 2003;15:458-463.
48. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24:1871-1886.
49. Bone HG, Adami S, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther. 2000;22:15-28.
50. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.
51. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-534.
52. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315-1322.
53. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res. 2001;16:104-112.
54. Frediani B, Falsetti P, Baldi F, et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis. Bone. 2003;33:575-581.
55. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
56. Souza SC, Borges C, Jorgetti V, Pereira RM. The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus. Rev Hosp Clin Fac Med Sao Paulo. 2004;59:302-305.
57. Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000;43:1960-1966.
58. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005;44:813-818.
59. Marini JC. Do bisphosphonates make children's bones better or brittle? N Engl J Med. 2003;349:423-426.
60. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:540-551.
61. Cranney A, Welch V, Adachi JD, et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis [Cochrane Review]. Oxford, England: Cochrane Library; 2003: Issue 4.
62. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res. 1992;7:1063-1069.
63. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738.
64. Vogelvang TE, van der Mooren MJ, Mijatovic V. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treat Endocrinol. 2004;3:105-115.
65. Ettinger B, Black DM, Mitlak BH, et al. Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
66. Reid IR, Ibbertson HK, France JT, Pybus J. Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. BMJ. 1985;291:574.
67. Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther. 2004;26:841-854.
68. Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:4528-4535.
69. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest. 1998;102:1627-1633.
70. Hodsman AB, Bauer DC, Dempster D, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26:688-703.
71. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-1215.
72. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000;85:2129-2134.
73. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med. 2004;350:459-468.
74. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949.
75. Bauer D, Mundy F, Jamal S, et al. Use of statins and fracture. Arch Intern Med. 2004;164:146-152.
76. Grey A, Reid IR. Emerging and potential therapies for osteoporosis. Expert Opin Investig Drugs. 2005;14:265-278.
77. Buckley LM, Hillner BE. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in prevention of vertebral fractures in women treated with glucocorticoid. J Rheumatol. 2003;30:132-138.
78. Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost effectiveness of alendronate therapy for osteopenic post-menopausal women. Ann Intern Med. 2005;142:734-741.
79. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-1503.